stem cell trial result out, page-3

Settle, its only a sidelines trial, not the main game - still on track q3>

Antisense Therapeutics Limited CEO and Managing Director Mark Diamond said “The stem cell mobilisation trial was designed with a clear therapeutic goal to provide clinical proof of concept to support the ongoing development of the drug in this specific application.

While this goal was not met in this trial, we were able to reach this decision point quickly and at relatively low expense.

In the short- term, with respect to ATL1102, we remain focussed on the ongoing development in the MS indication where we have already demonstrated potent clinical activity.”